These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23321466)

  • 1. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
    de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
    Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
    Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Lorente JA; Fumado L; Serrano L; Serrano S; Lloreta J; Hernández S
    Prostate; 2015 Aug; 75(11):1216-26. PubMed ID: 25939480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
    Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
    Svensson MA; Perner S; Ohlson AL; Day JR; Groskopf J; Kirsten R; Sollie T; Helenius G; Andersson SO; Demichelis F; Andrén O; Rubin MA
    Appl Immunohistochem Mol Morphol; 2014; 22(2):136-41. PubMed ID: 24517914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
    Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
    Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
    Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.